A Physiologic and Pharmacological Basis for Implementation of Incretin Hormones in the Treatment of Type 2 Diabetes Mellitus
- 31 December 2010
- journal article
- review article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 85 (12), S5-S14
- https://doi.org/10.4065/mcp.2010.0467
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetesBMC Endocrine Disorders, 2010
- Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on MetforminDiabetes Care, 2010
- Actos Now for the prevention of diabetes (ACT NOW) studyBMC Endocrine Disorders, 2009
- Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II studyThe Lancet, 2009
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 DiabetesDiabetes Care, 2009
- One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic PatientsDiabetes Care, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurrent Medical Research and Opinion, 2007
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007